A biopharmaceutical company focused on creating differentiated, value-added vaccines that improve upon current preventive options for a range of infectious diseases.


Updates from The Motley Fool

Latest updates on Novavax from Fool.com.  The Fool has written over 100 articles on Novavax.
2016's Worst Clinical Failures

It's been a rough year for drugmakers, but late clinical-stage failures made it especially tough ...

4 Stocks I'd Avoid at All Costs

Whether you're interested in these biotech stocks or not, there are some important lessons to be ...

3 Stocks to Avoid in Biotech

Buying biotech stocks has always been a risky business, but these three are best left on the shelf.



Stock Performance

View Interactive NVAX Charts
Sponsored by

Key Data Points

Primary metrics and data points about Novavax.
Current Price: $1.45
Prev Close: $1.45
Open: $1.54
Bid: $1.46
Ask: $1.47
Day's Range: $1.45 - $1.55
52wk Range: $1.16 - $8.49
Volume: 4,782,128
Avg Vol 6,750,923
Market Cap: $391M
P/E (ttm): -1.35
EPS (ttm): ($1.12)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Novavax.
CAPS Rating 2 out of 5
 
308 Outperform
82 Underperform
CAPS All Stars
 
43 Outperform
16 Underperform

How do you think Novavax will perform against the market?



You pick for Novavax is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Stanley C. Erck, CEO

75% Approve

Based on 22 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Novavax.

A biopharmaceutical company focused on creating differentiated, value-added vaccines that improve upon current preventive options for a range of infectious diseases.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers